International Prostate Symptom Score
International Prostate Symptom Score - Related Videos
02:34
Individual Lobe Extraction from Prostate: A Technique to Harvest Individual Prostate Lobes from Mouse Prostate
0 Views •
2023
This video describes a technique to harvest individual lobes from the prostate gland of a mouse model. Individual lobes can then be used for histological analysis and cancer research.
08:38
Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
0 Views •
Cited by 13 •
2013
We describe the manufacture of compressed hormone pellets, as well as subcutaneous surgical implantation into mice. This strategy can be combined with the growth of cell and tissue xenografts under the renal capsule of athymic nude mice to evaluate hormonal carcinogenesis and regulation of benign prostate growth.
11:29
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
0 Views •
Cited by 16 •
2015
Here we describe a simplified protocol for microRNA (miRNA) expression analyses in archived Formalin-Fixed, Paraffin-Embedded (FFPE) or fresh frozen prostate cancer (PCa) clinical tissues employing quantitative real-time PCR (RT-PCR) and in situ hybridization (ISH).
03:24
Extracting Prostate from Mouse Urogenital System: A Technique to Separate Prostate Gland from Other Urinary and Genital System Organs in Male Mouse
0 Views •
2023
In this video, we describe the procedure for the dissection of the urogenital system or UGS from a male mouse model. This UGS is further dissected ex vivo to isolate the prostate gland and study its role in prostate cancer development.
11:17
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
0 Views •
2025
This article presents a clinical protocol for repetitive transcranial magnetic stimulation (rTMS) with individualized symptom provocation in obsessive-compulsive disorder (OCD), following parameters from protocols cleared by the FDA.
FAQs
Interpretation centers on the combined symptom score rather than on any single urinary complaint. Responses across the seven items are added to produce a value from 0 to 35, which places symptom burden into mild, moderate, or severe categories. This provides clinicians with a consistent way to describe overall severity during evaluation and follow-up.
The quality-of-life item captures how urinary symptoms affect the patient’s personal experience, while the seven-item total summarizes symptom frequency and severity. Keeping these measures separate helps distinguish the amount of symptom burden from its perceived impact. Two patients with similar totals may therefore report different quality-of-life consequences, which can inform clinical discussions.
A one-month recall period gives the questionnaire a defined time frame for rating urinary symptoms. Patients assess how often or severely each listed problem occurred during that interval rather than relying on an unspecified general impression. Using the same period at later assessments supports more consistent comparisons when clinicians monitor symptom changes.
The patient rates each of the seven listed symptoms on the questionnaire’s 0-to-5 response scale and answers the separate quality-of-life item. A clinician then reviews the resulting symptom burden alongside the patient’s reported impact. The completed score supports evaluation and creates a standardized baseline for subsequent clinical decisions or reassessment.
IPSS results provide a structured measure of symptom burden that can support treatment discussions and clinical decision-making. The total score indicates overall severity, while the separate quality-of-life response shows how troublesome the symptoms are to the patient. Together, these results help place the patient’s reported experience into the broader evaluation of lower urinary tract symptoms.
Repeated administrations allow clinicians to compare symptom scores across different time points. A changing total can indicate that reported urinary symptom burden has improved or worsened, while the quality-of-life response shows whether the perceived impact has also changed. This longitudinal use makes the questionnaire useful for evaluating outcomes after clinical management.